ATE246244T1 - Rekombinante cmv-neutralisierungsproteine - Google Patents

Rekombinante cmv-neutralisierungsproteine

Info

Publication number
ATE246244T1
ATE246244T1 AT93203533T AT93203533T ATE246244T1 AT E246244 T1 ATE246244 T1 AT E246244T1 AT 93203533 T AT93203533 T AT 93203533T AT 93203533 T AT93203533 T AT 93203533T AT E246244 T1 ATE246244 T1 AT E246244T1
Authority
AT
Austria
Prior art keywords
polypeptides
proteins
recombinant cmv
glycoprotein
epitope
Prior art date
Application number
AT93203533T
Other languages
English (en)
Inventor
Carol A Pachl
Richard R Spaete
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE246244T1 publication Critical patent/ATE246244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93203533T 1988-01-29 1989-01-26 Rekombinante cmv-neutralisierungsproteine ATE246244T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14971588A 1988-01-29 1988-01-29

Publications (1)

Publication Number Publication Date
ATE246244T1 true ATE246244T1 (de) 2003-08-15

Family

ID=22531490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93203533T ATE246244T1 (de) 1988-01-29 1989-01-26 Rekombinante cmv-neutralisierungsproteine

Country Status (10)

Country Link
US (2) US6190860B1 (de)
EP (2) EP0436537A4 (de)
JP (2) JP2607712B2 (de)
AT (1) ATE246244T1 (de)
AU (1) AU641121B2 (de)
CA (1) CA1340832C (de)
DE (1) DE68929478T2 (de)
DK (1) DK176055B1 (de)
FI (1) FI109604B (de)
WO (1) WO1989007143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6162620A (en) * 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5552143A (en) * 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
GB9008223D0 (en) * 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
CA2124796A1 (en) * 1991-12-23 1993-07-08 Chiron Diagnostics Corporation Cmv probes for use in solution phase sandwich hybridization assays
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
CA2233060A1 (en) * 1995-09-26 1997-04-03 University Of Washington Glycoprotein b of the rfhv/kshv subfamily of herpes viruses
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
EP1137664A2 (de) * 1998-12-10 2001-10-04 Washington University Protein-transduktionssystem und methoden seiner verwendung
EP2286792A1 (de) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
AU2003301148A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
EP2451475A2 (de) 2009-07-06 2012-05-16 Novartis AG Selbstreplizierende rna-moleküle und ihre verwendung
EP2493911B1 (de) * 2009-10-30 2017-10-18 The Administrators of The Tulane Educational Fund Peptidzusammensetzungen und verfahren zur hemmung von herpesvirusinfektionen
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
EP3449910A1 (de) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Kationische öl-in-wasser emulsionen
EP2502631A1 (de) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
AU2012280901B2 (en) 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
CN107875382B (zh) 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
AU2014359276B2 (en) * 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
LT3471760T (lt) 2016-06-17 2025-02-25 Boehringer Ingelheim Vetmedica Gmbh Nauji imunogeniniai preparatai, apimantys linijinių arba šakotų poliakrilo rūgšties polimerų adjuvantus
EP3573649A4 (de) * 2017-01-27 2020-12-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Impfstoffzusammensetzungen aus herpesvirus-hüllprotein-kombinationen zur induktion einer immunreaktion
AU2019364823B2 (en) * 2018-10-25 2025-10-30 Km Biologics Co., Ltd. Modified CMV gB protein and CMV vaccine including same
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313927A (en) * 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4460689A (en) * 1982-04-15 1984-07-17 Merck & Co., Inc. DNA Cloning vector TG1, derivatives, and processes of making
US5173402A (en) * 1982-11-02 1992-12-22 The Regents Of The University Of California Method and compositions for screening and diagnosing human cytomegalovirus ("hCMV")
US4762780A (en) * 1984-04-17 1988-08-09 The Regents Of The University Of California Method and composition for screening and diagnosing "HCMV"
US4783399A (en) * 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE3585578D1 (de) * 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US5075213A (en) * 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
WO1987003602A1 (fr) * 1985-12-06 1987-06-18 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
CA1335429C (en) * 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
DE3619720A1 (de) * 1986-06-12 1987-12-17 Behringwerke Ag Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
JPH03504197A (ja) * 1988-05-09 1991-09-19 ザ・チルドレンズ・ホスピタル，インコーポレイテッド Ｈｃｍｖ糖タンパク質をコードしているベクターおよび発現産物
US5262297A (en) * 1990-06-18 1993-11-16 Eastman Kodak Company Specific binding analytical and separation methods using carboxy containing polymers
CA2124796A1 (en) * 1991-12-23 1993-07-08 Chiron Diagnostics Corporation Cmv probes for use in solution phase sandwich hybridization assays

Also Published As

Publication number Publication date
DK176055B1 (da) 2006-02-27
DK179290D0 (da) 1990-07-27
JPH09176190A (ja) 1997-07-08
JPH03503478A (ja) 1991-08-08
FI903724A0 (fi) 1990-07-25
US6190860B1 (en) 2001-02-20
EP0609580A1 (de) 1994-08-10
WO1989007143A1 (en) 1989-08-10
DK179290A (da) 1990-09-28
AU3041389A (en) 1989-08-25
FI109604B (fi) 2002-09-13
CA1340832C (en) 1999-11-30
AU641121B2 (en) 1993-09-16
DE68929478D1 (de) 2003-09-04
US5834307A (en) 1998-11-10
EP0436537A4 (en) 1992-04-08
EP0609580B1 (de) 2003-07-30
JP2607712B2 (ja) 1997-05-07
DE68929478T2 (de) 2004-04-29
EP0436537A1 (de) 1991-07-17

Similar Documents

Publication Publication Date Title
DE68929478D1 (de) Rekombinante CMV-Neutralisierungsproteine
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
DE69929533D1 (de) Immunotherapeutische methoden mit verwendung von wt-1 and gata-1 epitopen
LU88257I2 (de)
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
EP0837928A4 (de) Zusammensetzungen aus rekombinierten poxvirus-cytomegalovirus und ihre verwendung
DK1253201T3 (da) Kyllingeanæmivirusmutanter og vacciner baseret på det virale protein VP3 eller sekvenser af dette virus kodende derfor
NO882380D0 (no) Fibfonektin-bindende protein, samt fremstilling derav.
DE3751727D1 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
PT638316E (pt) Vacinas de adenoviros recombinante
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
DE68920502D1 (de) Pseudorabiesvirus-Impfstoff.
EP0433378A4 (en) Allelic variants of -i(plasmodium falciparum) merozoite surface antigen
Spaete et al. Recombinant CMV neutralizing proteins
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0609580

Country of ref document: EP

EELA Cancelled due to lapse of time